CNS Closes $1M Bridge Loan, Completes Clinical Trial Enrollment
The money will allow CNS Response, based in Costa Mesa, Calif., to complete an upcoming depression study.
Featured Articles
FDA Approves Kowa’s Cambia for Migraines
In clinical trials, Cambia provided statistically significant onset of relief of migraine pain within 15 to 30 minutes.
BioNeutral Ships Mold-Fighting Ogiene-M Formulation
BioNeutral, a life science company that specializes in biohazard neutralization technologies, has started shipping its Ogiene-M formulation to fulfill an agreement between BioNeutral and Mr. Mold.
Promising Genetic Biomarker Identified for Colorectal Cancer
A new genetic discovery could lead to easier detection of colorectal cancer.
Covidien Launches Nationwide Type 2 Diabetes Campaign
The Our Resolution movement is focused around the discovery that gastric bypass surgery resolves diabetes in approximately 77 percent of morbidly obese patients.
Clarient Launches New Gene Mutation Test for Lung Cancer
Clarient has launched a new gene mutation test to help physicians select the appropriate therapy for non-small cell lung cancer.
Frontrunners Emerge In Swine Flu Vaccine Race
Just days after the World Health Organization declared a swine flu pandemic, Fierce Biotech reports that two pharmaceutical companies are already racing to complete clinical trials of their H1N1 vaccines.
TearLab Wins Silver Medical Design Excellence Award
TearLab Corporation of San Diego announced that its TearLab Osmolarity System has received a Silver 2009 Medical Design Excellence Award.
Positive Results for Human Genome’s Lupus Drug Benlysta
Biotechnology company Human Genome Sciences reported that its drug candidate Benlysta reduced symptoms of lupus in a long-term clinical trial.
NeuroSearch’s Tesofensine Advances to Phase III Testing
Yesterday, OneMedPlace reported on several companies that are developing anti-obesity drugs. Another name can be added to the list.